Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06671977

Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans

The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects. We expect that DMT will induce changes in neuroplasticity as indexed using electroencephalographic (EEG) measures and tasks in both depressed individuals and healthy volunteers, though to different degrees. These neuronal changes may in parallel cause changes in mood measured both in healthy and depressed subjects, which will be captured using appropriate psychometric measures of mood.

Recruiting

Interested in participating?

Request Info

Key information

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,

West Haven, Connecticut, 06516, United States

Location status: Recruiting

Location contact

Deepak C D'Souza, MD

CONTACT

[email protected]

203-932-5711 ext. 14495

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Some Common Inclusion Criteria:

  • Males and females
  • Age 21 to 65 years
  • Body mass index between 18-35 kg/m2
  • Willing to refrain from taking any medications not approved by the study physician
  • Willing to refrain from using street drugs and alcohol
  • Negative urine drug screen
  • Willing and able to abstain from smoking throughout each test session
  • Women who are of child-bearing potential (WOCBP) and sexually active must be willing to practice an effective means of birth control
  • Willing not to drive to and from the testing session

Some Inclusion Criteria for Subjects with MDD:

  • Diagnosed with Major Depressive Disorder (MDD)
  • Unsatisfactory response to antidepressants
  • Engaged in treatment for depression with a clinician and willing to continue treatment for the duration of the study
  • Not engaged in treatment
  • Consent to allow the research team to communicate with mental health provider.
  • Only subjects who get support for participation in the trial from their mental health clinician will be eligible to be enrolled in the study

Some Common Exclusion Criteria:

  • Medications that might significantly interfere with the effects of the study medications
  • Cognitive dysfunction that could interfere with study participation
  • Alcohol or substance use disorder
  • Any lifetime history of hallucinogen use disorder
  • Regular use or misuse of hallucinogens
  • History of intolerance to perceptual altering drugs
  • Significant blood pressure problems
  • Pregnancy or currently breast feeding (lactation)
  • Any unstable medical conditions
  • Significant cardiovascular disease
  • Significantly abnormal laboratory test results
  • History of serotonin syndrome

Some Exclusion criteria for MDD subjects:

  • Current primary psychiatric disorder other than MDD
  • Medically significant condition rendering unsuitability for the study

Some Exclusion criteria for healthy controls:

  • No current DSM-V psychiatric disorder, excluding nicotine and caffeine use disorder
  • No family history of serious mental illness (e.g., schizophrenia, bipolar disorder)

Some Inclusion criteria for healthy controls:

  • No current DSM-5 psychiatric disorder, excluding nicotine and caffeine use disorder
  • No lifetime use of psychiatric medication >3 months (proxy for psychiatric disorders)

Treatment and study plan

DMT-Medium Dose

Drug

14 mg slow intravenous push (bolus) over 5 minutes and then 0.015 mg/kg/min for 55 minutes.

DMT-Low Dose

Drug

10 mg slow intravenous push (bolus) over 5 minutes and then 0.01 mg/kg/min for 55 minutes

THC-Medium Dose

Drug

0.5 mg over 5 minutes and then 2 mg over and 55 minutes

THC-Low Dose

Drug

0.1 mg slow intravenous push (bolus) over 5 minutes and then I mg over 55 minutes

Primary outcomes

  1. Safety of Physiological indices

    Time frame: Time Frame: -60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration]blood pressure and heart rate will be measured before, during, and after the dosing on each test day.

    Pulse oximetry will be measured continuously.

  2. Psychedelic Effects

    Time frame: From start Test Day Time points (Minutes): -60, +30, +120.

    The 30-item revised Mystical Experience Questionnaire (MEQ30) will be used to measure mystical/psychedelic experiences associated with drugs like psilocybin

  3. Psychotomimetic Effects

    Time frame: Test Day Time points (Minutes): -60, +30, +120

    To capture the effects of DMT/THC/placebo on perception, thought, and sensory processing, participants will be measured using the Psychotomimetic States Inventory

  4. Anxiety

    Time frame: Test Day Time points (Minutes): -60, +30, +120

    Will be assessed using a visual analog scale that subjects will be asked to score from 0 (not at all) to 100 (worst ever) to capture anxiety.

  5. Depression

    Time frame: From start of test day (-60), +30, and +120.

    subjects will be asked to score from 0 (not at all) to 100 (worst ever) to capture the depression.

  6. Intensity of the Experience

    Time frame: Test Day Time points (Minutes): +150 - +180

    The Challenging Experience Questionnaire (CEQ) a 26 item likert-scale style survey will be used to provide a phenomenological profile specifically of challenging aspects of experiences with psilocybin

  7. Drug Reinforcing Effects

    Time frame: Test Day Time points (Minutes): +120

    Will be assessed with questions such as:

    • How likely are you to use this drug recreationally? 0 (not at all) ------------------------100 (most of all)
    • How much are you willing to pay for the acute effects that you experienced during the dosing session? $0-------------------$100 Shortly after resolution of effects, participants will be instructed to retroactively rate the highest effects experienced since the last time they were prompted to provide a rating.
  8. Tolerability of Overt Adverse Effects

    Time frame: Test Day Time points (Minutes): -60, +30, +120, 180 (end of test day)

    Tolerability defined by the US FDA as "the degree to which overt adverse effects can be tolerated" by a subject was assessed [60]. At the end of the test day, after all drug effects have worn off, participants will be asked to score 1) the overall experience on a visual analog scale [VAS] (0 = intolerable to 100 = well-tolerated).

  9. Electrophysiological

    Time frame: Resting State EEG: Will be collected the day after each dosing session. [Time Frame: -60 minutes before DMT administration until +180 minutes after DMT administration].

Secondary outcomes

  1. Expectancy Effects

    Time frame: Subjects will be tested for expectancy effects at screening, and before each dosing session.

  2. Adequacy of blinding

    Time frame: Time Frame: 0; immediately after DMT administration, and +180 minutes at the end of the study

    Subjects will be asked to guess their treatment assignment, the degree of certainty of their guess and the reason for their guess both immediately after the psychedelic dosing session(s) and at the end of the study. Either the James' blinding index (BI) or Bang's BI, will be used to measure the adequacy of the blind.

  3. Blood

    Time frame: Blood sample measurements will be repeated approximately 0, 20, 30, and 60 minutes after drug administration

  4. Changes in personality domains (NEO personality inventory)

    Time frame: [Time Frame: -60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration]

  5. Psychological Flexibility

    Time frame: Time Frame: +180 minutes after DMT administration

    The Acceptance and Action Questionnaire (AAQ) is a one-factor, likert scale assessment of psychological inflexibility

Study contacts

Contact information is provided by the study sponsor or research team.

Deepak C D'Souza, MD

CONTACT

[email protected]

(203) 932-5711 ext. x12594

Sponsors and collaborators

Lead sponsor

Deepak C. D'Souza

Other

Registry information

Official study title

Phase 1 Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans

Acronym: DMT-Bolus

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Nov 4, 2024
Registry last updated
Jun 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.